COVID-19 Survivorship Registry
NCT04527315
Recruiting
COVID-19 is associated with acute pulmonary and cardiac injury. To better understand the degree and severity of cardiopulmonary injury as well as short and long-term sequelae of COVID-19 infection, this study will perform longitudinal study in patients who had recent known diagnosis of COVID-19.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: NYU Langone Health, New York, New York
Conditions: Covid19
Register for Updates
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
NCT04789044
Recruiting
The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is safe and effective for extending the half-life of circulating pharmaceutical products, when used in conjunction with a topical hemostatic agent in surgical wounds, and when used as a colon cleanser for endoscopic surgical procedures. However, PEG fusion has not been rigorously tested as a safe reagen... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/17/2024
Locations: University of Maryland Medical Center Shock Trauma Center, Baltimore, Maryland +6 locations
Conditions: Peripheral Nerve Injuries
Register for Updates
The PROTECT 2 Study : Pressure Injury Treatment by Intermittent Electrical Stimulation: A Randomized, Controlled Trial
NCT05085288
Recruiting
Multicentered randomized controlled study with adaptive design to evaluate if Intermittent Electrical Stimulation (IES) decreases progression and facilitates healing of pressure injuries for patients with, sacral / ischial pressure injuries.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: Wake Forest Unverisity, Winston-Salem, North Carolina +2 locations
Conditions: Stage 1 Pressure Ulcer, Stage 2 Pressure Ulcer
Register for Updates
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
NCT05119296
Recruiting
This is a single-arm, open-label trial designed to evaluate the activity of pembrolizumab therapy in anaplastic thyroid cancer in patients with no curative alternative therapy. Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression, intolerance of treatment, withdrawal of consent or death
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: Stanford University, Palo Alto, California
Conditions: Thyroid Cancer
Register for Updates
OurRelationship for Veteran Couples
NCT05136651
Recruiting
Access to a flexible spectrum of family-based VA mental health care for Veterans is mandated by law. Research shows that relationship distress harms Veterans' mental health, physical health, and mortality, while healthy relationships provide resilience and facilitate recovery from illness. However, there are many barriers to accessing couple and family care within VA, including system-level barriers such as insufficient access to specialty providers and couple-level barriers such as difficulty c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: VA San Diego Healthcare System, San Diego, CA, San Diego, California
Conditions: Relationship Distress
Register for Updates
Evaluating and Establishing the Relationship in the Five Critical X-ray Time Points in Spinal Deformity Realignment
NCT05154825
Recruiting
To establish the relationship in the five critical X-ray time points during multilevel posterior column osteotomies (MPCO) spinal deformity realignment in patients with adult spinal deformity and to follow the participants longitudinally to examine any follow-up X-rays and clinical data to compare to the post-operative standing scan and pre-operative data.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/17/2024
Locations: University of California, San Diego, San Diego, California
Conditions: Spine, Spine Deformity
Register for Updates
Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium
NCT05343572
Recruiting
This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
12/17/2024
Locations: Yale Fertility Center, Orange, Connecticut
Conditions: Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure
Register for Updates
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
NCT05443126
Recruiting
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: David Geffen School of Medicine at UCLA, Los Angeles, California +33 locations
Conditions: Advanced Solid Tumor
Register for Updates
Effect of Hypercapnia Treatment on Respiratory Recovery After Spinal Cord Injury
NCT05536076
Recruiting
It is estimated that 1,275,000 people in the United States alone live with spinal cord injury, including around 100,000 Veterans with spinal cord injury, making the V.A. the largest integrated health care system in the world for spinal cord injuries injury care. New therapies are needed to prevent the morbidities and mortalities associated with the high prevalence of respiratory disorders in Veterans with spinal cord injury. The current research project and future studies would set the base for... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
12/17/2024
Locations: John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan
Conditions: Sleep Apnea, SCI/D, Hypercapnia
Register for Updates
Transitioning Together Boston
NCT05599711
Recruiting
A randomized controlled trial will be conducted to determine the effects of an adapted family-centered autism transition intervention called Transitioning Together/Juntos en la Transición on meaningful outcomes for families. The study will occur in a safety net hospital setting. The adapted version of this multi-family group psychoeducation intervention is delivered across one individual family joining session and four 2.5 hour multi-family group sessions. The parent and youth groups are held in... Read More
Gender:
ALL
Ages:
Between 14 years and 21 years
Trial Updated:
12/17/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Autism or Autistic Traits, Family Relations
Register for Updates
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05633615
Recruiting
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may inter... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +75 locations
Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Register for Updates
Combination Therapy in Cancers With Mutations in DNA Repair Genes
NCT05694715
Recruiting
The purpose of this phase 1 clinical trials is to determine whether niraparib (a Poly (ADP-ribose) polymerase inhibitor (PARPi)) can be safely combined with irinotecan with manageable toxicity and reasonable efficacy. Emerging evidence suggest that PARPi is an effective therapeutic strategy in a wider subset of solid tumors that may have defective homologous recombination (HR) or DNA repair gene mutations. BReast CAncer gene (BRCA), partner and localizer of BRCA2 (PALB2), and various other DNA r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation
Register for Updates